Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERMOS: Effect of topical clobetasol on bone mineral density in bullous pemphigoid
2024-515676-12-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clobetasol in Bullous Pemphigoid (BP), sponsored by CHU Amiens-Picardie. Primary endpoint: Primary: Change in lumbar spine bone mineral density from baseline to 6 months. Planned start Jul 2024; status: authorised.
02
Drugs
clobetasol
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2024-515676-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515676-12-00.